New Jersey A 3621: Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Status: Introduced in the Assembly, Referred to Assembly Health Committee (as of 2024-02-12)

State: New Jersey · Session: 221 · Bill: A 3621

Subjects: PHARMACEUTIC

Sponsors: Murphy, Carol A.

View New Jersey A 3621 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.